Fianlimab/cemiplimab for melanoma (HARMONY)

Will this trial show a positive result on objective response rate (ORROutcome measureObjective Response Rate (ORR)Objective response rate is the share of patients whose tumors shrink by a predefined amount. It is useful for early signals and accelerated approval settings, but it is more surrogate than survival outcomes.Primary outcome | Up to 72 monthsClinicalTrials.gov outcome) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR)?